Dry Powder Inhaler (DPI) Market

The rising prevalence of respiratory diseases and other major driving factors is expected to favor the rise in the global dry powder inhalers (DPI) market

 

Reports and Insights has published a new report titled, “Dry Powder Inhaler (DPI) Market: Opportunity Analysis and Future Assessment 2020-2028

Global Dry Powder Inhalers (DPI) Market, By Product Type (Capsule-based Devices, Blister-based Devices, Reservoir/Cartridge-based Devices, Others), By Usability (Disposable, Reusable), By Dose (1 Single Dose, 1.1 Diskus, 1.2 Turbohaler, 1.3 Easyhaler, 1.4 Others, Multi-Dose, 1.1 Aerolizer, 1.2 Rotadisk, 1.3 Novolizer, Others), By Application (Bronchitis, Chronic Obstructive Pulmonary Diseases (COPD), Asthma, Others), By Sales Channel (Offline Channels, Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Channels, Other Sales Channels) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2020 and 2028.

The global dry powder inhalers (DPI) market in 2020 is estimated for more than US$ xx Bn and expected to reach a value of US$ xx Bn by 2028 with a significant CAGR of xx%.

A dry powdered inhaler (DPI) can be perceived as an asthma treatment alternative for teenagers and older kids. Employing a dry-powdered inhaler enables medicine to get deeply absorbed into the lungs. Contrary to other inhalers which release a gust of medicine, these dry powder inhalers keep the medicine as a dry powder.

Given that the medicine stays inside as a powder, one has to breathe in deep and fast to get the medicine into the lungs. DPIs generally need a quick, vigorous inhalation; for a certain number of patients, this might make a DPI more or less complex to use in the course of an asthma flare. Medication molecules in dry powder inhalers are powdered, not wet like a metered dose inhaler, and are so tiny they can reach the smallest airways.

Moreover, one may not even feel or taste the particles. Over the past few years, the world is witnessing growing prevalence of respiratory disorders owing to the worsening condition of the environment and rising levels of various pollutions as well as other significant factors, leading to growing importance and acceptance of pulmonary drug delivery among the population.

In addition to that, the numerous advantages associated with it including high bioavailability, quicker drug absorption, and indeginous action of the drug in the respiratory tract, enabling accelerated treatment and faster relief to patients undergoing from respiratory diseases, is further playing a major role in gaining patients’ compliance all across the world. Attributing to which, the global dry powder inhalers (DPIs) market is projected to rise significantly over the following years.

With the same token, in the merging regions, people are exposed to polluted and deteriorating air, which causes chronic disorders like asthma and chronic obstructive pulmonary diseases. Moreover, the sluggish lifestyle of the population, which includes lack of exercise, poor diet and smoking is further contributing to the increasing count of respiratory diseases among the population. Owing to which, the global dry powder inhaler market is expected to grow considerably in the forthcoming years.

Having said that, dry powdered inhalers may offer a drawback in comparison to the metered dose inhaler that there are odds of loss of the powdered medication in case of the accidental breathing out and thus it is likely to hold back the market growth in the near future. Furthermore, the DPIs contain traces of lactose which might not be suitable for lactose-intolerant patients, which may further slowdown the market growth in the coming years.

Reports and Insights Study identifies some of the key participating players in the dry powder inhalers (DPI) market globally are AstraZeneca, GlaxoSmithKline plc, Vectura Group plc., Boehringer Ingelheim GmbH, Otsuka Pharmaceutical Co. Ltd., Norton Healthcare, Lonza, Hovione, PureIMS BV, MannKind Corporation, TSRL, INC., TFF Pharmaceuticals, Respira, Spyryx Biosciences, Verona Pharma, ThinAir, Savara, Alviol, Advent Pharmaceuticals Pty, among others.

About Reports and Insights

Reports and Insights is one of the leading market research companies which offers syndicate and consulting research around the globe. At Reports and Insights we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with a strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us

Reports and Insights

Tel: +1-(718)-312-8686

For Sales Query: [email protected]

For New Topics & Other Info: [email protected]





This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

OK